Addex Therapeutics Ltd, a clinical-stage pharmaceutical company, announced that patient enrollment has been completed in its phase 2a clinical study evaluating dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.
A total of 15 patients have been enrolled into this double-blind, placebo controlled phase 2a feasibility study. The primary objective of the study is to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses. The effects on the severity and frequency of blepharospasm signs and symptoms using objective measures, clinical ratings and patient reported outcomes will also be evaluated as secondary endpoints. Data from the study are expected in Q2 2022.
